Production (Stage)
FibroBiologics, Inc.
FBLG
$0.8087
-$0.0638-7.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.77% | 10.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.06% | 10.74% | |||
| Operating Income | -22.06% | -10.74% | |||
| Income Before Tax | -60.25% | -519.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -60.25% | -519.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -60.25% | -519.80% | |||
| EBIT | -22.06% | -10.74% | |||
| EBITDA | -22.18% | -10.59% | |||
| EPS Basic | -49.12% | -509.40% | |||
| Normalized Basic EPS | -48.94% | -510.75% | |||
| EPS Diluted | -49.12% | -509.40% | |||
| Normalized Diluted EPS | -48.94% | -510.75% | |||
| Average Basic Shares Outstanding | 7.46% | 1.82% | |||
| Average Diluted Shares Outstanding | 7.46% | 1.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||